Tempus, Genmab Enter Oncology Biomarker Collaboration

Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that will leverage Tempus’ sequencing capabilities and platform of integrated clinical and molecular data with Genmab’s translational, biomarker and target discovery expertise. The companies will work together, based upon novel insights identified by Genmab, […]

Leave a Reply